Galectin Therapeutics Inc. (GALT)
NASDAQ: GALTHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 3.80 +4.97%
GALT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $365.08M
- EPS (TTM)
- -$0.43
- Dividend yield
- None
- 52-week range
- 2.03 – 7.13
- Day range
- 3.59 – 3.86
- Volume / Avg
- 175.98K / 387.94K
- Beta
- —
- Shares outstanding
- 100.85M
52-week range
GALT stock today
Shares of Galectin Therapeutics (GALT) finished lower on Oct 7 at $3.62, a drop of 3.72% or $0.14 per share, versus the S&P 500's 0.22% decline. Trading was light, with 175.98K shares changing hands, about 45% of the average daily volume. At this level, GALT sits in the middle of its 52-week range of $2.03 to $7.13: 49.2% below the high, set on Dec 17, 2025 and 78.3% above the low.
GALT is down 13.0% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 24.1%. Galectin Therapeutics has posted a net loss over the last twelve months (EPS of -$0.43), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Galectin Therapeutics
Company profileGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Joel Lewis CPA
- Headquarters
- Norcross, GA
- Employees
- 9
- Website
- galectintherapeutics.com
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$11.00+203.87%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Galectin Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| FENCFennec Pharmaceuticals Inc. | 10.36 | +0.10% | $363.30M | vs GALT |
| IRDOpus Genetics Inc. | 4.41 | +0.68% | $366.89M | vs GALT |
| ARCTArcturus Therapeutics Holdings Inc. | 12.77 | -1.81% | $362.82M | vs GALT |
| TTRXTurn Therapeutics Inc. | 12.10 | +3.95% | $367.45M | vs GALT |
| ENTAEnanta Pharmaceuticals Inc. | 12.37 | +1.64% | $360.28M | vs GALT |
| KYTXKyverna Therapeutics Inc. | 6.17 | +0.16% | $381.57M | vs GALT |
| CCCCC4 Therapeutics Inc. | 2.82 | -2.08% | $346.93M | vs GALT |
| RLMDRelmada Therapeutics Inc. | 3.25 | -0.91% | $346.68M | vs GALT |
Indexes, lists and sector
Appears in lists
Galectin Therapeutics stock FAQ
What is Galectin Therapeutics's stock price today?
GALT last traded at $3.62 as of Oct 7, 4:00 PM EDT, down 3.72% on the day. Prices are delayed at least 15 minutes.
Does Galectin Therapeutics pay a dividend?
No. Galectin Therapeutics does not currently pay a regular cash dividend.
Who is Galectin Therapeutics's CEO?
Mr. Joel Lewis CPA is the chief executive officer of Galectin Therapeutics Inc., which has about 9 employees.
Has GALT ever split its stock?
Yes. The most recent GALT stock split was a 1-for-6 split on Mar 23, 2012.
What is the GALT 52-week high?
The 52-week high for GALT is $7.13 and the 52-week low is $2.03. The stock is currently 49.2% below its high.